111011-76-8 | Efonidipine hydrochloride monoethanolate

Packsize	Purity	Availability	Price	Discounted Price
5mg	95%	in stock	$56.00	$39.00
10mg	95%	in stock	$99.00	$69.00
25mg	95%	in stock	$194.00	$136.00
50mg	95%	in stock	$260.00	$182.00
100mg	95%	in stock	$454.00	$318.00

Description

• Catalog Number: AD76905
• Chemical Name: Efonidipine hydrochloride monoethanolate
• CAS Number: 111011-76-8
• Molecular Formula: C36H45ClN3O8P
• Molecular Weight: 714.1846
• MDL Number: MFCD00875717
• SMILES: CC1=C(C(=O)OCCN(c2ccccc2)Cc2ccccc2)C(C(=C(N1)C)P1(=O)OCC(CO1)(C)C)c1cccc(c1)[N+](=O)[O-].CCO.Cl

Computed Properties

• Complexity: 1170
• Covalently-Bonded Unit Count: 3
• Heavy Atom Count: 49
• Hydrogen Bond Acceptor Count: 10
• Hydrogen Bond Donor Count: 3
• Rotatable Bond Count: 10
• Undefined Atom Stereocenter Count: 1

Literature

• Role of specific T-type calcium channel blocker R(-) efonidipine in the regulation of renal medullary circulation.

  Journal of hypertension 20120801

• T-type calcium channel blockade improves survival and cardiovascular function in thalassemic mice.

  European journal of haematology 20120601

• Effects of efonidipine on the pharmacokinetics and pharmacodynamics of repaglinide: possible role of CYP3A4 and P-glycoprotein inhibition by efonidipine.

  Journal of pharmacokinetics and pharmacodynamics 20120201

• Association of blood pressure control and metabolic syndrome with cardiovascular risk in elderly Japanese: JATOS study.

  American journal of hypertension 20111101

• Is metabolic syndrome a risk factor for cardiovascular disease in late elderly?

  American journal of hypertension 20111101

• Modulation of subthalamic T-type Ca(2+) channels remedies locomotor deficits in a rat model of Parkinson disease.

  The Journal of clinical investigation 20110801

• Efonidipine, a Ca(2+)-channel blocker, enhances the production of dehydroepiandrosterone sulfate in NCI-H295R human adrenocortical carcinoma cells.

  The Tohoku journal of experimental medicine 20110801

• Inhibitory effects of T/L-type calcium channel blockers on tubulointerstitial fibrosis in obstructed kidneys in rats.

  Urology 20110101

• Effect of efonidipine on TGF-β1-induced cardiac fibrosis through Smad2-dependent pathway in rat cardiac fibroblasts.

  Journal of pharmacological sciences 20110101

• Effects of S(+)-efonidipine on the rabbit sinus node action potential and calcium channel subunits Ca(V)1.2, Ca(V)1.3 and Ca(V)3.1.

  European journal of pharmacology 20101215

• Comparison of strict- and mild-blood pressure control in elderly hypertensive patients: a per-protocol analysis of JATOS.

  Hypertension research : official journal of the Japanese Society of Hypertension 20101101

• Efonidipine improves renal function and decreases proteinuria in elderly hypertensive patients in the JATOS study.

  Hypertension research : official journal of the Japanese Society of Hypertension 20101101

• Impact of renal function on cardiovascular events in elderly hypertensive patients treated with efonidipine.

  Hypertension research : official journal of the Japanese Society of Hypertension 20101101

• Is renal antiaging possible?

  Hypertension research : official journal of the Japanese Society of Hypertension 20101101

• Combination therapy with irbesartan and efonidipine for attenuation of proteinuria in Dahl salt-sensitive rats.

  Hypertension research : official journal of the Japanese Society of Hypertension 20100901

• Effects of enfonidipine hydrochloride in dogs with experimental supraventricular tachyarrhythmia.

  The Journal of veterinary medical science 20100701

• Effects of efonidipine, an L- and T-type calcium channel blocker, on the renin-angiotensin-aldosterone system in chronic hemodialysis patients.

  International heart journal 20100501

• Regulation of adrenal aldosterone production by serine protease prostasin.

  Journal of biomedicine & biotechnology 20100101

• T-type Ca channel blockade as a determinant of kidney protection.

  The Keio journal of medicine 20100101

• Protective effects of efonidipine, a T- and L-type calcium channel blocker, on renal function and arterial stiffness in type 2 diabetic patients with hypertension and nephropathy.

  Journal of atherosclerosis and thrombosis 20091001

• T-type Ca2+ channels promote oxygenation-induced closure of the rat ductus arteriosus not only by vasoconstriction but also by neointima formation.

  The Journal of biological chemistry 20090904

• T-type Ca2+ channel blockade prevents sudden death in mice with heart failure.

  Circulation 20090901

• Long-term effect of efonidipine therapy on plasma aldosterone and left ventricular mass index in patients with essential hypertension.

  Hypertension research : official journal of the Japanese Society of Hypertension 20090801

• Heterogeneity of L- and T-channels in the vasculature: rationale for the efficacy of combined L- and T-blockade.

  Hypertension (Dallas, Tex. : 1979) 20090401

• Azelnidipine inhibits aldosterone synthesis and secretion in human adrenocortical cell line NCI-H295R.

  European journal of pharmacology 20090301

• Molecular pharmacology of human Cav3.2 T-type Ca2+ channels: block by antihypertensives, antiarrhythmics, and their analogs.

  The Journal of pharmacology and experimental therapeutics 20090201

• Effects of efonidipine hydrochloride on heart rate and circulatory changes due to stress.

  Clinical and experimental hypertension (New York, N.Y. : 1993) 20090201

• Development of newer calcium channel antagonists: therapeutic potential of efonidipine in preventing electrical remodelling during atrial fibrillation.

  Drugs 20090101

• Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS).

  Hypertension research : official journal of the Japanese Society of Hypertension 20081201

• Spectroscopic studies on the interaction of efonidipine with bovine serum albumin.

  Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas 20080701

• A selective T-type Ca2+ channel blocker R(-) efonidipine.

  Naunyn-Schmiedeberg's archives of pharmacology 20080601

• Species difference in the contribution of T-type calcium current to cardiac pacemaking as revealed by r(-)-efonidipine.

  Journal of pharmacological sciences 20080501

• T-type calcium channel blockade as a therapeutic strategy against renal injury in rats with subtotal nephrectomy.

  Kidney international 20080401

• T-type Ca2+ channel blockers prevent cardiac cell hypertrophy through an inhibition of calcineurin-NFAT3 activation as well as L-type Ca2+ channel blockers.

  Life sciences 20080312

• Beneficial effects of the dual L- and T-type Ca2+ channel blocker efonidipine on cardiomyopathic hamsters.

  Circulation journal : official journal of the Japanese Circulation Society 20071201

• Comparison of the effects of efonidipine and amlodipine on aldosterone in patients with hypertension.

  Hypertension research : official journal of the Japanese Society of Hypertension 20070801

• Efonidipine reduces proteinuria and plasma aldosterone in patients with chronic glomerulonephritis.

  Hypertension research : official journal of the Japanese Society of Hypertension 20070701

• Efonidipine simultaneously improves blood pressure, endothelial function, and metabolic parameters in nondiabetic patients with hypertension.

  Diabetes care 20070601

• Effects of benidipine in a rat model for experimental angina.

  Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 20061201

• [JATOS].

  Nihon rinsho. Japanese journal of clinical medicine 20060801

• Blocking T-type Ca2+ channels with efonidipine decreased plasma aldosterone concentration in healthy volunteers.

  Hypertension research : official journal of the Japanese Society of Hypertension 20060701

• Inhibitory effect of efonidipine on aldosterone synthesis and secretion in human adrenocarcinoma (H295R) cells.

  Journal of cardiovascular pharmacology 20060101

• Actions of mibefradil, efonidipine and nifedipine block of recombinant T- and L-type Ca channels with distinct inhibitory mechanisms.

  Pharmacology 20060101

• Divergent action of calcium channel blockers on ATP-binding cassette protein expression.

  Journal of cardiovascular pharmacology 20051201

• Pathophysiological significance of T-type Ca2+ channels: T-type Ca2+ channels and drug development.

  Journal of pharmacological sciences 20051101

• Pathophysiological significance of T-type Ca2+ channels: role of T-type Ca2+ channels in renal microcirculation.

  Journal of pharmacological sciences 20051101

• Beneficial effect of T-type calcium channel blockers on endothelial function in patients with essential hypertension.

  Hypertension research : official journal of the Japanese Society of Hypertension 20051101

• The Japanese Trial to Assess Optimal Systolic Blood Pressure in Elderly Hypertensive Patients (JATOS): protocol, patient characteristics, and blood pressure during the first 12 months.

  Hypertension research : official journal of the Japanese Society of Hypertension 20050601

• Identification of R(-)-isomer of efonidipine as a selective blocker of T-type Ca2+ channels.

  British journal of pharmacology 20041201

• The R(-)-enantiomer of efonidipine blocks T-type but not L-type calcium current in guinea pig ventricular myocardium.

  Journal of pharmacological sciences 20041201

• A comparison between calcium channel blocking drugs with different potencies for T- and L-type channels in preventing atrial electrical remodeling.

  Journal of cardiovascular pharmacology 20040901

• Clinical efficacy of efonidipine hydrochloride, a T-type calcium channel inhibitor, on sympathetic activities.

  Circulation journal : official journal of the Japanese Circulation Society 20030201

• Effect of efonidipine and ACE inhibitors on proteinuria in human hypertension with renal impairment.

  American journal of hypertension 20030201

• Effects of efonidipine hydrochloride on renal arteriolar diameters in spontaneously hypertensive rats.

  Hypertension research : official journal of the Japanese Society of Hypertension 20020901

• Effects of efonidipine on platelet and monocyte activation markers in hypertensive patients with and without type 2 diabetes mellitus.

  Journal of human hypertension 20020801

• Efonidipine hydrochloride: a dual blocker of L- and T-type ca(2+) channels.

  Cardiovascular drug reviews 20020101

• Divergent renal vasodilator action of L- and T-type calcium antagonists in vivo.

  Journal of hypertension 20011101

• Divergent natriuretic action of calcium channel antagonists in mongrel dogs: renal haemodynamics as a determinant of natriuresis.

  Clinical science (London, England : 1979) 20011001

• Effects of the antihypertensive drug nifedipine on albuminuria and renal histopathology in young spontaneously hypertensive rats with diabetes.

  General pharmacology 19991101